The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Georgia Boyce Vogelsang - One of the best experts on this subject based on the ideXlab platform.
-
Novel strategies for steroid-refractory acute Graft-Versus-Host Disease.
Current Opinion in Hematology, 2020Co-Authors: Javier Bolaños-meade, Georgia Boyce VogelsangAbstract:Purpose of review Graft-Versus-Host Disease is one of the commonest complications of allogeneic bone marrow or peripheral blood stem cell transplantation. This review will cover advances in the pathophysiology of Graft-Versus-Host Disease and new agents under investigation for the treatment of this disorder. Patients developing Graft-Versus-Host Disease who fail to respond to steroids have a poor prognosis. In this group of people, morbidity and mortality are very high. Recent findings Novel agents are currently under investigation for the treatment of such devastating disorders. Pentostatin, denileukin diftitox, mycophenolate mofetil, extracorporeal photopheresis, and several monoclonal antibodies have been used, some of them with encouraging results. Summary As supportive care improves and new agents are added to the armamentarium against steroid-refractory acute Graft-Versus-Host Disease, the prognosis of this entity may start to change. Patients with this complication after transplantation should be enrolled, whenever possible, in clinical trials to find effective therapies.
-
Overlap subtype of chronic Graft-Versus-Host Disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-Versus-Host Disease Consortium study
Haematologica, 2011Co-Authors: Joseph Pidala, Georgia Boyce Vogelsang, Steven Z. Pavletic, Corey Cutler, Paul Martin, Xiaoyu Chai, Barry E. Storer, Daniel J. Weisdorf, Madan Jagasia, Jeanne PalmerAbstract:Background The National Institutes of Health Consensus Conference proposed the term “overlap” graft- versus -host Disease to describe the situation when both acute and chronic graft- versus -host Disease are present. Design and Methods We examined whether the overlap subtype of graft- versus -host Disease was associated with a different prognosis, functional limitations, or patient-reported outcomes compared to “classic” chronic graft- versus -host Disease without any acute features. Results Prospective data were collected from 427 patients from nine centers. Patients were classified as having overlap (n=352) or classic chronic (n=75) graft- versus -host Disease based on reported organ involvement. Overlap cases had a significantly shorter median time from transplantation to cohort enrollment ( P =0.01), were more likely to be incident cases ( P
-
Sensitivity of changes in chronic graft- versus -host Disease activity to changes in patient-reported quality of life: results from the Chronic Graft- versus -Host Disease Consortium
Haematologica, 2011Co-Authors: Joseph Pidala, Georgia Boyce Vogelsang, Steven Z. Pavletic, Corey Cutler, Xiaoyu Chai, Daniel J. Weisdorf, Brenda F. Kurland, Navneet S. MajhailAbstract:Background The 2005 National Institute of Health Chronic Graft- versus -Host Disease Consensus Conference recommended collection of patient-reported outcomes in clinical trials on chronic graft- versus -host Disease. We assessed whether changes in chronic graft- versus -host Disease severity, determined using National Institute of Health criteria, clinicians’ assessment or patients’ self-evaluation, correlated with patient-reported quality of life as measured by the Short Form-36 and Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT) instruments. Design and Methods Three-hundred and thirty-six adult patients (median age 52 years; range, 19 – 79) with chronic graft- versus -host Disease from six transplant centers contributed baseline and follow-up data (from 936 visits overall). Results While the majority of the patients had stable chronic graft- versus -host Disease, improvement or worsening was noted in approximately 40% of follow-up visits. Multivariable analysis demonstrated no association between change in chronic graft- versus -host Disease severity evaluated by National Institute of Health criteria and change in quality of life, while clinician-reported changes in severity were associated with changes in some quality of life measures. Patient-reported changes in the severity of chronic graft- versus -host Disease were associated with changes in all quality of life measures. Comparison of the Short Form-36 and the FACT-BMT suggested that the data collected in the Functional Assessment of Cancer Therapy – General (FACT-G) core survey are sufficient without the need for the Short Form-36 or the FACT–BMT subscale. Conclusions We conclude that serial National Institute of Health and clinician-reported chronic graft- versus -host Disease severity assessments cannot substitute for patient-reported outcomes in clinical trials. Collection of just the FACT-G instead of the Short Form-36 and the full FACT-BMT will decrease respondent burden without compromising quality of life assessment.
-
Chronic Graft-Versus-Host Disease
Current Pharmaceutical Design, 2008Co-Authors: Javier Bolaños-meade, Georgia Boyce VogelsangAbstract:Chronic Graft-Versus-Host Disease is the most common late, non-relapse complication of transplantation yet it is also one of the least studied. It is the primary cause of morbidity and mortality of long-term survivors ofallogeneic bone marrow transplants. Like acute Graft-Versus-Host Disease, it does have a strong antitumor effect. The recent National Institutes of Health sponsored Chronic Graft-Versus-Host Disease Consensus Conference has proposed new criteria for diagnosis and staging, pathology, biomarkers, response and supportive care. New understanding of the pathophysiology of chronic Graft-Versus-Host Disease (i.e. the role of B cells) is already having an impact on therapy. Novel agents such as pentostatin, mycophenolate mofetil, rituximab, extracorporeal photochemotherapy, etc. are improving the outcome of steroid refractory chronic Graft-Versus-Host Disease.
-
Acute Graft-Versus-Host Disease.
Clinical advances in hematology & oncology, 2004Co-Authors: Javier Bolaños-meade, Georgia Boyce VogelsangAbstract:Acute Graft-Versus-Host Disease (aGVHD) continues to be a problem in allogeneic transplantation. Recent advances in the understanding of the induction and propagation of GVHD have lead to new transplant strategies and treatment of aGVHD. This overview covers the basic pathophysiology, prophylaxis and treatment of this disorder.
Muriel M. Schornack - One of the best experts on this subject based on the ideXlab platform.
-
Ocular Graft-Versus-Host Disease: A review
Eye and Contact Lens, 2015Co-Authors: Saranya C. Balasubramaniam, Harish Raja, Cherie B. Nau, Joanne F. Shen, Muriel M. SchornackAbstract:Graft-Versus-Host Disease (GVHD) is a common cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Systemic findings involving the skin, gastrointestinal tract, and liver often overshadow the other manifestations of GVHD. Ocular surface Disease remains the most common cause of long-term morbidity in GVHD. Herein, the etiology, pathophysiology, clinical manifestations, and treatment of acute and chronic systemic GVHD are reviewed, with a focus on ocular GVHD. © 2013 Elsevier Inc.
Saranya C. Balasubramaniam - One of the best experts on this subject based on the ideXlab platform.
-
Ocular Graft-Versus-Host Disease: A review
Eye and Contact Lens, 2015Co-Authors: Saranya C. Balasubramaniam, Harish Raja, Cherie B. Nau, Joanne F. Shen, Muriel M. SchornackAbstract:Graft-Versus-Host Disease (GVHD) is a common cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Systemic findings involving the skin, gastrointestinal tract, and liver often overshadow the other manifestations of GVHD. Ocular surface Disease remains the most common cause of long-term morbidity in GVHD. Herein, the etiology, pathophysiology, clinical manifestations, and treatment of acute and chronic systemic GVHD are reviewed, with a focus on ocular GVHD. © 2013 Elsevier Inc.
Sharon R Hymes - One of the best experts on this subject based on the ideXlab platform.
-
Graft-Versus-Host Disease: part I. Pathogenesis and clinical manifestations of Graft-Versus-Host Disease.
Journal of the American Academy of Dermatology, 2020Co-Authors: Sharon R Hymes, Amin M Alousi, Edward W CowenAbstract:Approximately 25,000 allogeneic hematopoietic cell transplants are performed worldwide each year for a variety of malignant and non-malignant conditions. Graft-Versus-Host Disease represents one of the most frequent complications and is a major source of long-term morbidity and mortality. Whereas acute Graft-Versus-Host Disease is induced by recognition of host tissues as foreign by immunocompetent donor cells, the pathogenesis of chronic Graft-Versus-Host Disease is not as well understood, and continues to be a major treatment challenge. Part I of this two-part series reviews the epidemiologic factors, classification, pathogenesis, and clinical manifestations of acute and chronic Graft-Versus-Host Disease. Part II discusses the topical, physical, and systemic treatment options available to patients with Graft-Versus-Host Disease.
-
Graft-Versus-Host Disease: part II. Management of cutaneous Graft-Versus-Host Disease.
Journal of the American Academy of Dermatology, 2020Co-Authors: Sharon R Hymes, Amin M Alousi, Edward W CowenAbstract:Dermatologists are ideally suited to manage the various cutaneous sequelae of Graft-Versus-Host Disease (GVHD) outlined in part I of this review. However, the complexity of the patient with GVHD, including comorbidities, potential drug interactions related to polypharmacy, and the lack of evidence-based treatment guidelines, are significant challenges to optimizing patient care. In this section, we will provide an outline for the role of the dermatologist in a multispecialty approach to caring for patients with GVHD.
-
Graft-Versus-Host Disease
Journal of The American Academy of Dermatology, 2012Co-Authors: Sharon R Hymes, Amin M Alousi, Edward W CowenAbstract:Dermatologists are ideally suited to manage the various cutaneous sequelae of Graft-Versus-Host Disease (GVHD) outlined in part I of this review. However, the complexity of the patient with GVHD, including comorbidities, potential drug interactions related to polypharmacy, and the lack of evidence-based treatment guidelines, are significant challenges to optimizing patient care. In this section, we will provide an outline for the role of the dermatologist in a multispecialty approach to caring for patients with GVHD.
-
Epidermodysplasia verruciformis in the setting of Graft-Versus-Host Disease
Journal of The American Academy of Dermatology, 2007Co-Authors: Joy H. Kunishige, Sharon R Hymes, Vandana Madkan, Angela J. Wyatt, David Uptmore, Alexander J. Lazar, Sergio Giralt, Peter L. Rady, Stephen K. TyringAbstract:We report a case of epidermodysplasia verruciformis (EV)-like lesions in a patient with Graft-Versus-Host Disease after peripheral blood stem cell transplantation from his HLA-matched brother. The patient presented with a diffuse papular eruption that was clinically consistent with Graft-Versus-Host Disease; however, histopathology demonstrated viral cytopathic changes and polymerase chain reaction confirmed EV human papillomavirus types 8 and 20. Repeated biopsy specimen showed both human papillomavirus cytopathic effect and Graft-Versus-Host Disease, and further workup revealed ocular and hepatic involvement. This progressed to a lupuslike syndrome with lichenoid, violaceous, flat-topped papules in a malar distribution and positive antinuclear autoantibodies. Although EV-like lesions have been reported in patients who are immunocompromised, the incidence is low, and may be linked to EV-related haplotypes.
-
Cutaneous Manifestations of Chronic Graft-Versus-Host Disease
Biology of Blood and Marrow Transplantation, 2006Co-Authors: Sharon R Hymes, Maria L. Turner, Richard E. Champlin, Daniel R. CourielAbstract:Abstract Cutaneous chronic graft versus host Disease has traditionally been classified into lichenoid and scleroderma-like forms. However, the initial presentation is sometimes subtle and a variety of less common cutaneous manifestation may be prevalent. This clinical review focuses on the lesional morphology of chronic graft versus host Disease, and presents a classification system that may prove useful in early diagnosis. In addition, this approach may help to facilitate the correlation of different morphologic entities with outcome and response to therapy.
Edward W Cowen - One of the best experts on this subject based on the ideXlab platform.
-
Graft-Versus-Host Disease: part I. Pathogenesis and clinical manifestations of Graft-Versus-Host Disease.
Journal of the American Academy of Dermatology, 2020Co-Authors: Sharon R Hymes, Amin M Alousi, Edward W CowenAbstract:Approximately 25,000 allogeneic hematopoietic cell transplants are performed worldwide each year for a variety of malignant and non-malignant conditions. Graft-Versus-Host Disease represents one of the most frequent complications and is a major source of long-term morbidity and mortality. Whereas acute Graft-Versus-Host Disease is induced by recognition of host tissues as foreign by immunocompetent donor cells, the pathogenesis of chronic Graft-Versus-Host Disease is not as well understood, and continues to be a major treatment challenge. Part I of this two-part series reviews the epidemiologic factors, classification, pathogenesis, and clinical manifestations of acute and chronic Graft-Versus-Host Disease. Part II discusses the topical, physical, and systemic treatment options available to patients with Graft-Versus-Host Disease.
-
Graft-Versus-Host Disease: part II. Management of cutaneous Graft-Versus-Host Disease.
Journal of the American Academy of Dermatology, 2020Co-Authors: Sharon R Hymes, Amin M Alousi, Edward W CowenAbstract:Dermatologists are ideally suited to manage the various cutaneous sequelae of Graft-Versus-Host Disease (GVHD) outlined in part I of this review. However, the complexity of the patient with GVHD, including comorbidities, potential drug interactions related to polypharmacy, and the lack of evidence-based treatment guidelines, are significant challenges to optimizing patient care. In this section, we will provide an outline for the role of the dermatologist in a multispecialty approach to caring for patients with GVHD.
-
Graft-Versus-Host Disease
Journal of The American Academy of Dermatology, 2012Co-Authors: Sharon R Hymes, Amin M Alousi, Edward W CowenAbstract:Dermatologists are ideally suited to manage the various cutaneous sequelae of Graft-Versus-Host Disease (GVHD) outlined in part I of this review. However, the complexity of the patient with GVHD, including comorbidities, potential drug interactions related to polypharmacy, and the lack of evidence-based treatment guidelines, are significant challenges to optimizing patient care. In this section, we will provide an outline for the role of the dermatologist in a multispecialty approach to caring for patients with GVHD.
